Jonathan Wong

Jonathan Wong

The Latest

  • Microsoft Q4: Cloud Revenue Surges Amid Hardware Sales Slump, Shares Down 5% in After-hours Trading
    DATA CENTER
    Despite these gains, Microsoft's shares fell 5% in after-hours trading, reflecting investor concerns over slower-than-expected growth in key areas.
  • Merck Faces Stock Decline Amid Gardasil Sales Slump in China and Adjusted Profit Forecast
    NEW PILL ON THE BLOCK
    Merck & Co. experienced its steepest stock drop in three years following a mixed second-quarter earnings report that highlighted lower-than-expected sales of its Gardasil HPV vaccine in China. Despite surpassing profit and revenue estimates, the disappointing performance of Gardasil overshadowed the company's quarterly achievements, leading to a significant market reaction.
  • Spirit Airlines Revamps Services with Premium Perks to Compete with Larger Rivals
    Spirit Airlines Revamps Services with Premium Perks to Compete with Larger Rivals
    In a bold move to elevate its brand and attract a broader range of travelers, Spirit Airlines announced a significant overhaul of its fare structure on Tuesday. Known for its budget-friendly approach, the Florida-based carrier is set to introduce new service packages that bundle various amenities previously offered à la carte. This strategic shift comes as Spirit grapples with challenges including a blocked takeover by JetBlue, engine recalls, and stiff competition in a saturated domestic market.
  • Procter & Gamble Reports Earnings Beat but Faces Challenges in Chinese Market
    Procter & Gamble’s Another Quarter Of Strong Sales
    Procter & Gamble (P&G) reported its fiscal fourth-quarter earnings on Tuesday, exceeding Wall Street's expectations in terms of earnings per share but falling short in revenue, largely due to disappointing demand in China. This mixed performance has led to a 5% drop in the company's stock during morning trading.
  • Pfizer Beats Earnings Expectations, Raises Full-Year Forecast Amid Cost-Cutting Measures
    Pfizer
    Pfizer Inc., the pharmaceutical giant known for its significant contributions during the COVID-19 pandemic, has reported second-quarter earnings and revenue that surpassed Wall Street expectations. The company also raised its full-year outlook, driven by strong sales of its COVID-19 antiviral pill Paxlovid, robust performance from its non-COVID products, and a broad cost-cutting initiative.
  • BP to Reward Shareholders with $7 Billion Buyback Despite Falling Profits
    BP Oil
    British oil giant BP PLC announced a substantial $7 billion stock buyback plan for 2024, even as it grapples with a near 30% decline in profits for the first half of the year. This move comes as the company faces criticism for prioritizing shareholder returns over more aggressive climate action.
  • BMW, Chrysler, Ford, and Maserati Among Automakers Issuing Major Car Recalls
    BMW Innovation Base Shanghai
    The National Highway Traffic Safety Administration (NHTSA) recently issued multiple recalls affecting over 313,000 vehicles from various automakers, including BMW, Chrysler, Ford, and Maserati. These recalls address a range of issues from safety hazards to incorrect information labels, reflecting ongoing efforts to maintain vehicle safety standards.
  • McDonald's Q2 Earnings Miss Expectations Amid Consumer Pullback
    McDonald's
    McDonald's reported disappointing second-quarter earnings on Monday, highlighting the ongoing challenges faced by the fast-food giant as consumers become more price-sensitive. The company missed Wall Street estimates across the board, revealing that even dominant players in the fast-food industry are not immune to current economic pressures.
  • Apple Reaches Landmark Labor Agreement with Maryland Store Workers
    Apple
    In a groundbreaking move for labor relations within the tech industry, Apple and the union representing employees at its Towson, Maryland store have reached a tentative agreement. This marks the first labor deal for Apple store workers in the United States and signifies a major milestone in the growing movement for unionization across the tech sector.
  • Abbott Ordered to Pay $495M Over Infant Formula Linked to Severe Disease
    Abbott Ordered to Pay $495M Over Infant Formula Linked to Severe Disease
    A St. Louis jury on Friday delivered a landmark verdict against Abbott Laboratories, ordering the healthcare company to pay $495 million in damages over claims that its specialized formula for premature infants caused a severe bowel disease in a young girl. This case is the first of hundreds of similar lawsuits against the company, marking a significant moment in ongoing legal battles concerning the safety of infant formulas.
Prev81   82   83   84   85   86   87   88   89   90  Next